Acura Pharmaceuticals, Inc.

Equities

ACUR

US00509L8028

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 10:26:06 2024-04-19 am EDT			5-day change	1st Jan Change
0.01 ^USD	+257.14%		0.00%	+9,900.00%

Mar. 26	Acura Pharmaceuticals, Inc. Announces Amendment to the Agreement with Abuse Deterrent Pharma, LLC	CI
Mar. 14	Acura Pharmaceuticals, Inc. announced that it has received $0.25 million in funding from Abuse Deterrent Pharma, LLC	CI

Acura Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021

June 30, 2023 at 11:54 am EDT

Acura Pharmaceuticals, Inc. reported earnings results for the fourth quarter ended December 31, 2021. For the fourth quarter, the company reported revenue was USD 0.036 million compared to USD 0.718 million a year ago. Net income was USD 0.029 million compared to net loss of USD 0.243 million a year ago.

Latest news about Acura Pharmaceuticals, Inc.

Acura Pharmaceuticals, Inc. Announces Amendment to the Agreement with Abuse Deterrent Pharma, LLC	Mar. 26	CI
Acura Pharmaceuticals, Inc. announced that it has received $0.25 million in funding from Abuse Deterrent Pharma, LLC	Mar. 13	CI
Acura Pharmaceuticals, Inc. Receives $250,000 Loan from Abuse Deterrent Pharma, LLC	Feb. 14	CI
Acura Pharmaceuticals, Inc. announced that it has received $0.25 million in funding	Feb. 13	CI
Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharmaceuticals, LLC Enter into Amendment #1 to the November 10, 2022 Amended, Consolidated and Restated Secured Promissory Note	Dec. 21	CI
Acura Pharmaceuticals, Inc. Announces Retirement and Resignation of Mr. Bruce F. Wesson as Member of Board of Directors	23-09-25	CI
Acura Pharmaceuticals, Inc. Provides Update Related to LTX-03 (Hydrocodone Bitartrate and Acetaminophen) Tablets	23-08-31	CI
Acura Pharmaceuticals, Inc. Announces Preliminary Topline Results from Study AP-LTX-311 Successfully Demonstrated That A Nine-Tablet Dose of Ltx-03	23-08-30	CI
Acura Pharmaceuticals, Inc. and Zyla Life Sciences, LLC Agree to Terms for the Termination of the Collaboration and License Agreement	23-08-16	CI
Acura Pharmaceuticals, Inc. Receives $250,000 Loan from Abuse Deterrent Pharma, LLC	23-07-28	CI
Acura Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	23-06-30	CI
Acura Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	23-06-30	CI
Acura Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	23-06-29	CI
Acura Pharmaceuticals, Inc. Enters into an Agreement to Further Amend the June 28, 2019 License, Development and Commercialization Agreement with Abuse Deterrent Pharma, LLC	23-06-28	CI
Acura Pharmaceuticals, Inc. Receives $150,000 Loan from Abuse Deterrent Pharma, LLC	23-05-26	CI
Acura Pharmaceuticals, Inc. Provides Development Update on LTX-03	23-02-13	CI
Acura Pharmaceuticals, Inc. Announces First Clinical Study for Its Investigational Drug LTX-03	23-02-02	CI
Acura Pharmaceuticals, Inc. announced that it has received $2.319279 million in funding from Abuse Deterrent Pharma, LLC	22-11-09	CI
Acura Pharmaceuticals, Inc. announced that it has received $0.25 million in funding	22-10-12	CI
Acura Pharmaceuticals, Inc. Receives $250,000 Loan from John Schutte	22-08-26	CI
Acura Pharmaceuticals, Inc. announced that it has received $0.25 million in funding	22-08-22	CI
Acura Pharmaceuticals, Inc. announced that it has received $0.15 million in funding	22-07-17	CI
Acura Pharmaceuticals, Inc Enters into License, Development and Commercialization Agreement with Abuse Deterrent Pharmaceuticals LLC	22-07-14	CI
Acura Pharmaceuticals, Inc. Receives $150,000 Loan from John Schutte	22-07-11	CI
Acura Pharmaceuticals, Inc. announced that it has received $0.1 million in funding	22-05-19	CI

Chart Acura Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Acura Pharmaceuticals, Inc. is a drug delivery company engaged in the research, development, and commercialization of technologies and products to address the safe use of medications. Its platform technologies include LIMITX Technology, AVERSION Technology, and IMPEDE Technology. Its LIMITX Technology is designed to minimize the risks and side effects associated with overdose by retarding the release of active drug ingredients when too many tablets are accidentally or purposefully ingested. The LIMITX Technology is in development with hydrocodone bitartrate and acetaminophen (also known as LTX-03) as the lead product candidates. Its AVERSION Technology is to address methods of product tampering associated with opioid abuse by incorporating gelling ingredients and irritants into tablets to discourage abuse by snorting and provide barriers to abuse by injection. Its IMPEDE Technology is directed at minimizing the extraction and conversion of pseudoephedrine tablets into methamphetamine.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ACURA PHARMACEUTICALS, INC.	+9,900.00%	663K
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs